Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.
Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
Funds will support UK commercial launch and FDA 510(k) submission later this year
The combined companies will have revenue drivers of two commercially available diagnostics tools, Cologuard and Oncotype DX.
The new company will be helmed by Mylan’s Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
Gemphire will enter into the reverse merger following a strategic review of its options.
MorphoSys AG will publish its first six months’ 2019 results on August 6, 2019 at 10:00pm CEST.